LMICs struggle in the process of selecting potent drugs at suitable prices – Dr. Iyad Sultan

Italian hospitals have been treating children with cancer with Celginase, a drug unapproved in the EU but legal due to regulatory gaps. This drug, a form of L-asparaginase manufactured in Southern Asia, is one of the most important drugs in treating leukemia. It is a cheaper but substandard option for acute lymphoblastic leukemia, often used without patients’ knowledge. The situation highlights the urgent need for regulatory reform and greater transparency in drug import practices across EU.  LMICs struggle in the process of selecting potent drugs at suitable prices, and such regulations may help Healthcare Scandal.

For details: Click here

Source: Dr. Iyad Sultan/Twitter